anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is a three-arm, multi-center, randomized controlled trial. Participants will be recruited in this study, with participants in each group. This trial is reported on the basis of the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidelines and complies with the principles of the Consolidated Standards of Reporting Trials (CONSORT) and Standards for Reporting Interventions in Clinical Trial of Acupuncture (STRICTA).The study will be carried out from January 2023 to December 2023 at five hospitals in China. Those hospitals include the first hospital of Hunan university of Chinese Medicine, Chengdu university of traditional Chinese medicine, Jiangsu Province Hospital of Chinese Medicine, The Affiliated Hospital of Jiangxi University of TCM, and Guizhou university of TCM. This research will recruit participants with ED by outpatient and inpatient department and social media. The patients who meet the diagnostic criteria of American Urological Association will be included in this study. The eligible patients with ED will be allocated into three groups: the liver meridian group, the stomach meridian group, and the non-acupoint group in a 1:1:1 ratio. The total observation period is twenty weeks, including a one-week baseline, eight-week treatment period, and twelve-week follow-up period. Outcome evaluation will be implemented at the baseline, during the treatment period, and during the follow-up period.
PURPOSE:To prepare an enteric capsule comprising a content coated with a coating film base material produced by crosslinking gelatin and carrageenan with ions. CONSTITUTION:Fats and oils containing unsaturated fatty acids as a content are coated with a coating film base material to provide an enteric capsule. The coating film base material is produced by mixing 100 pts. of gelatin, 1-40 pts. of carrageenan and a proper amount of water, adjusting the pH of the mixture to 3-5, and subsequently crosslinking the adjusted mixture with ions at 60-90 deg.C. The crosslinking of the gelatin and the carrageenan enables to obtain the enteric capsule coating base material which does not cause the mutual adhesion of the capsules even at high temperatures in the summer, is not dissolved in gastric juice, but is dissolved in intestinal juice. This capsule coating film base material has a high gas-barrier property and enables to produce soft capsules, hard capsules and seamless capsules.
This study will replicate the evidence-based TOP™ in after-school sessions held during RC hours. The primary components of TOP™ include: Comprehensive age-appropriate sexuality education; 90-minute sessions, once a week after-school, during the school year for nine months, using the Changing Scenes© curriculum, and at least twenty hours of youth-led service learning, which involves youth in planning, implementing and reflecting on, community service and leadership.
Group with patients treated in the public health system in Brazil. They will be stratified according to whether or not CDK 4/6 inhibitors are used in therapy.
This research was conducted to determine the effect of applying heat to the soles of the feet during the active and transition phase (4-10 cm dilation) of the first stage of labor. The research is a randomized controlled experimental study and is conducted in Sivas Cumhuriyet University Practice and Research Hospital Maternity Unit. When the sample size was taken as α = 0.05 and β = 0.10 and 1-β = 0.90 to represent the population in the research, there were 30 individuals in each group and the power of the test was found to be P = 0.90640. The application procedure started with the application of hot gel packets at a temperature of 40-42°C to the soles of the feet of the women in the intervention group for 20 minutes when cervical dilation reaches 5 cm. The first Visual Analog Scale (VAS) evaluation was conducted after the application. Conduction is followed by more evaluations at the 25th (5 minutes after the application), 35th (15 minutes after the application), and 50th minute (30 minutes after the application). These applications were repeated every hour until cervical dilation reached 10 cm. The applicatilon procedure has been stopped after cervical dilation reached 10 cm. The control group received routine service and VAS at the same times. Data were collected with personal information form, Partograph form, APGAR score, Visual Analog Scale (VAS) and Birth Satisfaction Scale Short Form (BSS-R) Wilcoxon test, Mann Whitney U test, Chi-square test, Exact test, Friedman test, t test were used to evaluate the data. The data error level was accepted as 0.05.
The Wii Fit training was conducted using the Wii Fit bundle from Nintendo, which consists of the Wii console, a Wii Balance Board, and the Wii Fit Plus balance game disc. The Wii balance board has 4 transducers, which could assess the player's force distribution and resultant movements in the center of pressure (COP). The participants stood on the board and used the change of COP to play the games. Five games (Tilt, Soccer Heading, Balance Bubble, Penguin Slide, and Perfect 10) were selected from the Wii Fit Plus package based on the motor demand of these games. The major movement patterns to play the games included right-left weight shifting and front-back weight shifting.
Targets nonverbal imitation, match-to-sample, verbal imitation, imitation of play activities, receptive language, and expressive language. 5 hours per week of individual instruction for 4 months (Two 30-minute sessions per day, five days per week) with reductions in classroom pull out sessions in months 5 and 6 with implementation of 1 hour per week of in-home parent training for the last 2 months.
The pollution posed by medical waste complicate the procedures of medical waste logistics (MWL), and the increasingly frequent occurrence of public health emergencies has magnified the risks posed by it. In this study, the authors established an index of the factors influencing the risks posed by MWL along five dimensions: the logistics business, emergency capacity, equipment, personnel, and management. The best-worst case method was used to identify the critical risk-related factors and rank them by importance. Following this, we assessed the risk posed by MWL in four major cities in China as an example and propose the corresponding measures of risk control. The results showed that the linking of business processes was the most important factor influencing the risk posed by MWL. The other critical risk-related factors included the location of the storage site, the capacity for emergency transportation, measures to manage emergencies, and the safety of packaging. Of the cities considered, Beijing was found to be a high-risk city, and its MWL needed to be improved as soon as possible in light of the relevant critical risks. Shanghai, Guangzhou, and Shenzhen were evaluated as general-risk cities, which meant that the risks of MWL were not a priority in these areas, and the other goals of urban development should be comprehensively considered during the long-term planning for MWL in these municipalities.
Virtual Reality Therapy that includes use of VR goggle, VR headset and play station if available. Virtual games like move-pro will be used for upper limb movements. A session of 12-45 minutes, twice weekly will be done. And scoring will be done with the help of additional tools.
Wheelchair-bound Senior Elastic Band (WSEB) exercise program has three phases: 1) warm-up: 6 movements to loosen up the body and elevate the energy for a safe transition to the next phase, 2) aerobic motions: 6 low-to-medium speed exercises to enhance the cardiovascular-respiratory workout, and 3) static stretching: 6 low-speed, gentle stretching exercises to build up muscle power/endurance and increase range of motion and flexibility. It is conducted three times per week, 40 minutes per practice.
PCT No. PCT/US93/09387 Sec. 371 Date Apr. 20, 1995 Sec. 102(e) Date Apr. 20, 1995 PCT Filed Oct. 1, 1993 PCT Pub. No. WO94/07918 PCT Pub. Date Apr. 14, 1994This invention relates to antithrombotic agents and uses thereof. Specifically, the invention relates to chemical moieties that specifically bind to platelets and inhibit their aggregation, including linear and cyclic peptides. The invention provides methods for using these antithrombotic agents to prevent the formation of thrombi at sites in a mammalian body. In particular, the platelet-specific binding moieties including linear and cyclic peptides of the invention are covalently linked to a polyvalent linker moiety, so that the polyvalent linker moiety is covalently linked to a multiplicity of the platelet-specific binding moieties including linear and cyclic peptides. Efficacious antithrombotic agents are thereby provided.
The FBSFT condition includes 17 weekly family-based treatment sessions at the hospital obesity clinic followed by monthly follow-up sessions with their local nurse and follow-up sessions at the hospital every third month for 2 years.The treatment targets both child and parent life-style; eating habits, physical activity, sedentary activity and sleep habits. Behavior modification techniques are systematically employed; such as self-monitoring, goal setting, reward systems, problem solving and stimulus control. In addition, FBSFT focuses on facilitating lifestyle change across different settings (family, friends, school and community) and harnessing social support for healthy habits, which is considered important for long-term weight control.
Clinicians at participating sites will be asked to refer adult patients with rifampin-resistance identified by routine molecular testing. The investigators aim to enroll 100-200 patients per year at each of three enrollment sites for evaluation of novel rDST assays.
Embodiments of a graphical user interface (GUI), display module, and method for displaying and comparing skin features are generally described herein. A pose panel may display a body outline or thumbnail image of one of several body poses and may identify one or more alerts. Each alert may identify skin features that have been identified as changed. An alert image panel may display a higher-resolution image of the alert selected in the pose panel showing identified skin features. An alert information panel may display alert data associated the alerts and may indicate a review status associated with the alerts. An alert notes panel may display notes associated with a selected alert. The GUI may be configured to systematically display the alerts associated with the poses in sequence to automate and help expedite the process of reviewing identified skin-features.
The invention discloses a rabeprazole sodium enteric-coated pellet capsule and a preparation method thereof. The capsule is internally provided with a rabeprazole sodium enteric-coated pellet. The rabeprazole sodium enteric-coated pellet successively comprises a blank pellet core, a drug-containing layer, an insulation layer and an enteric-coated layer from the inside to the outside. The drug-containing layer comprises Rabeprazole sodium, an adhesive and a pH conditioning agent. The pH conditioning agent is composed of one or two components selected from sodium hydroxide, magnesium oxide, sodium carbonate and sodium bicarbonate. According to the technical scheme of the invention, the drug-containing layer is provided with the pH conditioning agent, and the isolation layer is arranged between the drug-containing layer and the enteric-coated layer. Therefore, the alkaline drug-containing layer is prevented from getting in contact with the acidulous enteric-coated layer. The enteric-coated layer is provided with a non-water-soluble plasticizer, thus being excellent in stability and acid tolerance. The enteric-coated layer can be quickly released in a pH 6.8 medium. The drug quality attributes of the above Rabeprazole sodium enteric-coated pellet capsule are kept consistent with those of original enteric-coated pellet capsules, so that the quality stability of drugs is ensured. the preparation method is simple to operate, low in production cost and high in efficiency, thus being suitable for large-scale industrial production.
For this project, the study team is proposing to retrospectively analyze a de-identified data set of these data to report on pilot data on preliminary outcomes, acceptability and feasibility of the implementation of the COMPASS: Acting Mindfully for a Valued Life, based upon Acceptance and Commitment Therapy, an evidence-based behavioral intervention and facilitated by a licensed clinical psychologist in our department. This intervention was implemented as a series of clinical offerings for seven 7-session groups between September 2015 and October 2018 for 113 individual cancer patients and survivors. Outcomes measured include anxiety, depression, fear of recurrence, psychological flexibility, mindfulness; values based living, and quality of life. Participants completed surveys at 4 time points, pre and post, and two followup time points. Measures of demographics, satisfaction and feasibility/acceptability were also collected. Insights gathered from this study will be used to inform articles, grant applications and conference presentations on the implementation of behavioral interventions for cancer patients and survivors.
Clusters 3 and 4 (group 2) that serve as control group of cluster 1 and 2 (group 1), will also complete the assessment at T1. Clusters 3 and 4 (group 2) will start the intervention in step 2, after completing the second assessment.
The invention relates to an application of ginkgolic acid in preparation of an external preparation for treating dermatopathy. The ginkgolic acid comprises ginkgoic acid, ginkgol, ginkgo diphenol, and the like, and can be obtained from extracts of leaves, fruit, exopleura, and rhizome of ginkgo by a chemical separation method. The dermatopathy is infectious, inflammatory, allergic or anaphylactic dermatopathy. External preparations of ginkgolic acid-containing medicaments, cosmetics, or disinfectants for treating dermatopathy comprises 0.001-80% (by weight) of ginkgolic acid, and pharmaceutically common external preparation substrates or acceptable carriers; the preparation has any pharmaceutical dosage form. Pharmacological experimental research shows that the preparation of the invention has significant effect of anti-infection of skin resident pathogens, anti-inflammation, antianaphylaxis, anti-allergy, analgesia, itching relief, and wound heal promotion. Clinical trials show that the preparation of the invention has significant treatment effect on various dermatopathy, has an effective rate of up to 100%, is safe and has no side effect.
BACKGROUND: Adipocytokines play a pivotal role in maintaining adipose tissue homeostasis by regulating cellular metabolism, proliferation, differentiation, and secretory activity. These soluble factors are relevant components for healthy adipose tissue, while their deficiency is closely associated with the development of obesity and related metabolic diseases, e.g., chronic inflammation. In human adipose tissue, inter-α-trypsin inhibitor heavy chain 5 (ITIH5) is expressed in proportion to the development of adipose tissue, i.e., the individual's BMI. Thus, ITIH5 has been proposed to be an inert marker of human obesity. However, when applied to adipose stem cells in vitro, recombinant (r)ITIH5 protein inhibited proliferation and adipogenesis, suggesting that ITIH5 negatively affects the development of fat mass. We now tested the role of ITIH5 in vivo and compared ITIH5+/+ wildtype with ITIH5-/- knockout mice.
RESULTS: Genetic deletion of ITIH5 significantly increased adipose tissue mass relative to animal bodyweight (p < 0.05). Next, we characterized adipose stem cells (ASCs) from both genotypes in vitro. ITIH5-/- cells exhibited increased proliferation and adipogenic differentiation (p < 0.001), which could explain the increase in adipose tissue in vivo. Furthermore, ASCs from ITIH5-/- animals were more responsive to stimulation with inflammatory mediators, i.e., these cells released greater amounts of IL-6 and MCP-1 (p < 0.001). Importantly, the application of the rITIH5 protein reversed the observed knockout effects in ASCs.
CONCLUSIONS: Our data suggest that ITIH5 potently regulates adipose tissue development and homeostasis by modulating ASC biology in mice. In addition, the effect of the rITIH5 protein underscores its potential as a therapeutic agent to correct the adipose tissue dysregulation often associated with obesity and metabolic disorders.
The colon cleansing efficacy of SUTAB was evaluated in two randomized, single-blind, active-controlled, multicenter trials (Study 1 and Study 2). These trials included adult subjects undergoing colonoscopy for colorectal cancer screening and surveillance, or diagnostic colonoscopy, including subjects with abdominal pain, diarrhea, constipation and non-severe inflammatory bowel disease.

In Study 1 (BLI4700-301; NCT 03404401), 548 adult patients were included in the efficacy analysis. Patients ranged in age from 19 to 84 years (median age 59 years) and 56% were female. Racial distribution was 78% Caucasian, 16% African-American, and 11% Hispanic or Latino. Patients were randomized to one of the following two colon preparation regimens: SUTAB or polyethylene glycol 3350, sodium sulfate, sodium chloride, potassium chloride, ascorbic acid and sodium ascorbate for oral solution. Both preparations were administered according to a split-dose regimen [see Dosage and Administration ( 2.2)] . Patients receiving SUTAB were limited to a low residue breakfast followed by clear liquids on the day prior to the day of colonoscopy; patients receiving the comparator bowel prep were allowed to have a normal breakfast and a light lunch, followed by clear liquids and/or yogurt for dinner. Approximately 97% of patients in the study completed both doses of preparation (98% of SUTAB patients and 95% of comparator patients). 

In Study 2 (BLI4700-302; NCT 03261960), 388 adult patients were included in the efficacy analysis. Patients ranged in age from 23 to 83 years (median age 58 years) and 58% were female. Racial distribution was 94% Caucasian, 9% Hispanic or Latino, and 5% African-American. Patients were randomized to one of the following two colon preparation regimens: SUTAB or sodium picosulfate, magnesium oxide, and anhydrous citric acid for oral solution. Both preparations were administered according to a split-dose regimen [see Dosage and Administration ( 2.2)] . Patients receiving SUTAB were limited to a low residue breakfast followed by clear liquids on the day prior to the day of colonoscopy; patients receiving the comparator bowel prep were only allowed clear liquids on the day prior to colonoscopy. Approximately 98% of patients in the study completed both doses of preparation (98% of SUTAB patients and 99% of comparator patients). 

The primary efficacy endpoint in each trial was the proportion of patients with successful colon cleansing, as assessed by the blinded colonoscopist utilizing the four-point scaled described below. Success was defined as an overall cleansing assessment of 3 (Good) or 4 (Excellent).

Results for the primary endpoint in Studies 1 and 2 are shown in Table 3. In both trials, SUTAB was non-inferior to the comparator.
A drug delivery device for delivering a drug to a subject is provided. The drug delivery device includes a housing, a drug reservoir supported by the housing containing the drug and a hollow microneedle supported by the housing. The hollow microneedle is moveable from an inactive position to an activated position, wherein, when the hollow microneedle is moved to the activated position, the tip portion of the hollow microneedle is configured to penetrate the skin of the subject. The drug delivery device includes a channel having an input in communication with the drug reservoir and an output in communication with the hollow microneedle. The channel provides fluid communication between the drug reservoir and the hollow microneedle, such that the drug is permitted to flow from the drug reservoir through the channel and through the hollow microneedle. The channel moves from a first position to a second position as the hollow microneedle moves from the inactive position to the activated position, and the position of the drug reservoir relative to the housing remains fixed as the hollow microneedle moves from the inactive position to the activated position.
The data described for Trials 1 and 2 reflect exposure to Cathflo Activase in 1122 patients, of whom 880 received a single dose and 242 received two sequential doses of Cathflo Activase.

In the Cathflo Activase Trials 1 and 2, only limited, focused types of serious adverse events were recorded, including death, major hemorrhage, intracranial hemorrhage, pulmonary or arterial emboli, and other serious adverse events not thought to be attributed to underlying disease or concurrent illness. Major hemorrhage was defined as severe blood loss ( > 5 mL/kg), blood loss requiring transfusion, or blood loss causing hypotension. Non‑serious adverse events and serious events thought to be due to underlying disease or concurrent illness were not recorded. Patients were observed for serious adverse events until catheter function was deemed to be restored or for a maximum of 4 or 6 hours depending on study. For most patients the observation period was 30 minutes to 2 hours. Spontaneously reported deaths and serious adverse events that were not thought to be related to the patient's underlying disease were also recorded during the 30 days following treatment.

Four catheter-related sepsis events occurred from 15 minutes to 1 day after treatment with Alteplase, and a fifth sepsis event occurred on Day 3 after Alteplase treatment. All 5 patients had positive catheter or peripheral blood cultures within 24 hours after symptom onset.

Three patients had a major hemorrhage from a gastrointestinal source from 2 to 3 days after Alteplase treatment. One case of injection site hemorrhage was observed at 4 hours after treatment in a patient with pre-existing thrombocytopenia. These events may have been related to underlying disease and treatments for malignancy, but a contribution to occurrence of the events from Alteplase cannot be ruled out. There were no reports of intracranial hemorrhage.

Three cases of subclavian and upper extremity deep venous thrombosis were reported 3 to 7 days after treatment. These events may have been related to underlying disease or to the long-term presence of an indwelling catheter, but a contribution to occurrence of the events from Alteplase treatment cannot be ruled out. There were no reports of pulmonary emboli.

There were no gender-related differences observed in the rates of adverse reactions. Adverse reactions profiles were similar across all age subgroups.
Since the completion of the STIC trial in 2017, the french team continues to offer DBS of the globus pallidus internus (GPi) to selected, treatment-refractory patients with TS. On average, three to four patients undergo surgery every year. Even though a first follow-up of the STIC cohort up to four years post-op indicates ongoing improvement of tic severity, many questions remains regarding the efficacy of GPi DBS in TS. These questions include frequent comorbidities of TS, quality of life, evolution of medication and stimulation parameters, as well as neuropsychological functioning. Therefore, the investigator proposes to evaluate all patients undergoing GPi DBS for TS to be evaluated comprehensively pre-operatively and once yearly after surgery until reaching the 5-year mark. The investigator team hopes these data may help to plan for future international multicenter trials, and provide indications on prognostic factors concerning response to GPi DBS in TS.
Multiple-Dose XP21279 (with Lodosyn®) treatment. Upon completion of Sinemet® treatment eligible subjects will be placed on a fixed dosing time regimen of XP21279 (with Lodosyn®).